분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2007-08-07 12:12:14 , Hit : 4977
 Gene therapy trial on hold

2007.07.31

As the US Food and Drug Administration prepares to investigate the death of a patient in a phase I/II gene therapy trial for inflammatory arthritis, researchers in the field say the treatment's delivery vector, an adeno-associated virus (AAV), was unlikely to be the culprit.

"Vectors in this class have been used on hundreds of patients over the last 12 years, and are not associated with acute toxicity," said Terence Flotte of the University of Massachusetts Medical School in Worcester. Flotte has been a principal investigator in several clinical trials of AAV-based gene therapy, but is not associated with the trial in question. "I've never seen anything like this," he told The Scientist. "Whatever this is, it's unusual."

"The AAV vectors in themselves are unlikely to cause inflammation or cell damage," agreed Theodore Friedmann of the University of California, San Diego, previous president of the American Society of Gene Therapy. Although he cautioned against speculating in the absence of clinical data, Friedmann noted that the transgene the vector encoded could have caused the patient's reaction. "It's a powerful transgene," said Friedmann. "It might have induced a massive immune response of some sort."

Mark Kay of the Stanford University School of Medicine in Palo Alto, Calif., cited the excellent safety record adeno-associated viruses had both in animal and human studies. Kay, who has led trials that used these vectors, said however that in the present case he did not rule out the possibility of an acute immunological response to the AAV itself.

The FDA placed the trial on hold after the company sponsoring it, Targeted Genetics of Seattle, told the agency on July 20 that the patient had suffered a serious adverse event in response to the treatment. The patient died on July 24.

In the trial, the AAV vector delivered a transgene encoding the receptor for tumor necrosis factor (TNF)-alpha, a cytokine that causes joint swelling in arthritis patients. The receptor, secreted by the target cells, binds to TNF-alpha, to reduce inflammation and protect the joint.

Usually prescribed for autoimmune conditions such as rheumatoid arthritis, the TNF-alpha receptor works by suppressing the immune system. But the protein could also have opened the door to an infection, suggested Flotte.

According to a July 28 article in the Washington Post, the trial had raised safety concerns when it was proposed in 2003, including the fear that the viruses might spread from the joint to the whole body. Reviewers appointed by the National Institutes of Health's Recombinant DNA Activities Committee also questioned the usefulness of the study, since animal data had showed only a limited value for the therapy. However, the trial was eventually approved and progressed without serious side effects, according to a company official quoted by the Post.

In 1999, teenager Jesse Gelsinger died of multiple organ failure four days after getting gene therapy for a genetic liver disease. That vector, an adenovirus, was proved to be the direct cause of death. Since then, however, adenoviruses have been used in several trials without such incidents.

Adeno-associated viruses, also used in about a half-a-dozen ongoing gene therapy clinical trials, are thought to be safer than adenoviruses or retroviruses because they lack viral coding sequences in their genome and do not replicate.

Since the trial started in October 2005, 127 patients have received an initial injection of either the active drug or the placebo, according to Targeted Genetics. The patient's death came after getting a second injection, which contained the active drug, but the company has not disclosed whether his or her first injection was an active dose or a placebo...








1067   Foamy 바이러스 벡터를 이용한 유전자 치료  이성욱 2008/02/12 5778
1066   Foot-and-mouth culls could be cut  이성욱 2011/05/11 3155
1065   Former Reginans changing the future of HIV  이성욱 2011/12/28 2256
1064   Fragile X syndrome: Trigger for most common form of intellectual disability and autism uncovered  이성욱 2014/03/05 1770
1063   Frances H. Arnold, George P. Smith, and Gregory P. Winter share 2018 Nobel Prize in Chemistry  이성욱 2018/10/04 357
1062   Friends connect on a genetic level  이성욱 2011/01/24 2262
1061   From Startups to Moguls] CRISPR 유전자가위 없이 편집한다? Homology Medicines  이성욱 2017/09/11 605
1060   Gene Editing Treats Blood Disease  이성욱 2011/07/16 3017
1059   Gene Study Based on RNA Interference May Lead to New Liver Cancer Therapies  이성욱 2017/08/14 810
1058   Gene Therapy Allows Beethoven Mouse to Hear  이성욱 2015/07/10 874
1057   Gene Therapy Appears to Help Patient With Anemia  이성욱 2010/09/17 2908
1056   Gene therapy drug approval granted to GSK  이성욱 2016/05/30 934
1055   Gene Therapy Ever More Common for Rare Disorders  이성욱 2018/05/30 333
1054   Gene Therapy for Controlling HIV Shows Early Promise  이성욱 2014/03/08 1599
1053   Gene Therapy for Immune Disorder Lasts Nine Years, Two New Studies Show  이성욱 2011/08/25 2478
1052   Gene Therapy May Thwart HIV  이성욱 2011/09/23 2055
1051   Gene therapy offers hope for Parkinson's disease  이성욱 2011/03/23 2352
1050   Gene Therapy Shows Promise Against Age-Related Macular Degeneration  이성욱 2011/05/04 2542
1049   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2434
  Gene therapy trial on hold  이성욱 2007/08/07 4977

[이전 10개] [1].. 11 [12][13][14][15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN